Neumora Therapeutics
pivotal studies designed to evaluate potential benefits of in | Neumora Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2023
Slide
13 of 32
Related slides by other companies
Dare Bioscience
Investor Presentation
February 2023
advancing products women want late stage programs cream dare | Dare Bioscience
Dare Bioscience
Investor Presentation
February 2023
advancing products women want the portfolio snapshot | Dare Bioscience
MindMed
Investor Presentation
November 2024
for gad phase program overview | MindMed
Erasca
Investor Presentation
January 2024
pivotal phase and phase trial designs capitalize on promising efficacy signals and support potential successful registration in multiple indications setae dor secondary | Erasca
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights